m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00165)
Target Name ATP-binding cassette sub-family C member 9 (ABCC9)
Synonyms
Sulfonylurea receptor 2; SUR2
    Click to Show/Hide
Gene Name ABCC9
Chromosomal Location 12p12.1
Family ABC transporter superfamily; ABCC family; Conjugate transporter (TC 3;A;1;208) subfamily
Function
Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation.
    Click to Show/Hide
Gene ID 10060
Uniprot ID
ABCC9_HUMAN
HGNC ID
HGNC:60
Ensembl Gene ID
ENSG00000069431
KEGG ID
hsa:10060
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
ABCC9 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line ARPE-19 cell line Homo sapiens
Treatment: shMETTL3 ARPE-19 cells
Control: shControl ARPE-19 cells
 GSE202017
Regulation
logFC: -1.97E+00
p-value: 5.10E-08
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between ABCC9 and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 6.69E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary TRIM11 regulates nasopharyngeal carcinoma drug resistance by positively modulating the Daple/beta-catenin/ATP-binding cassette sub-family C member 9 (ABCC9) signaling pathway. TRIM11 enhanced the multidrug resistance in NPC by inhibiting apoptosis in vitro and promoting cisplatin (DDP) resistance in vivo. METTL3-mediated m6A modification caused the upregulation of TRIM11 via IGF2BP2 in NPC drug-resistant cells.
Target Regulation Down regulation
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response ABC transporters hsa02010
Wnt signaling pathway hsa04310
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
In-vitro Model CNE-1 Normal Homo sapiens CVCL_6888
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model A total of 2 × 106 cells was mixed with 0.2 ml PBS (pH 7.4) and 30% (v/v) Matrigel matrix (BD Biosciences).
Nasopharyngeal carcinoma [ICD-11: 2B6B]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary TRIM11 regulates nasopharyngeal carcinoma drug resistance by positively modulating the Daple/beta-catenin/ATP-binding cassette sub-family C member 9 (ABCC9) signaling pathway. TRIM11 enhanced the multidrug resistance in NPC by inhibiting apoptosis in vitro and promoting cisplatin (DDP) resistance in vivo. METTL3-mediated m6A modification caused the upregulation of TRIM11 via IGF2BP2 in NPC drug-resistant cells.
Responsed Disease Nasopharyngeal carcinoma [ICD-11: 2B6B]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response ABC transporters hsa02010
Wnt signaling pathway hsa04310
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
In-vitro Model CNE-1 Normal Homo sapiens CVCL_6888
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model A total of 2 × 106 cells was mixed with 0.2 ml PBS (pH 7.4) and 30% (v/v) Matrigel matrix (BD Biosciences).
Cisplatin [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary TRIM11 regulates nasopharyngeal carcinoma drug resistance by positively modulating the Daple/beta-catenin/ATP-binding cassette sub-family C member 9 (ABCC9) signaling pathway. TRIM11 enhanced the multidrug resistance in NPC by inhibiting apoptosis in vitro and promoting cisplatin (DDP) resistance in vivo. METTL3-mediated m6A modification caused the upregulation of TRIM11 via IGF2BP2 in NPC drug-resistant cells.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
Pathway Response ABC transporters hsa02010
Wnt signaling pathway hsa04310
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
In-vitro Model CNE-1 Normal Homo sapiens CVCL_6888
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model A total of 2 × 106 cells was mixed with 0.2 ml PBS (pH 7.4) and 30% (v/v) Matrigel matrix (BD Biosciences).
References
Ref 1 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the Beta-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis. 2020 May 7;9(5):45. doi: 10.1038/s41389-020-0229-9.